Welcome to our dedicated page for Qiagen SEC filings (Ticker: QGEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
QIAGEN N.V. filings document the reporting of a Netherlands-based foreign private issuer with common shares traded under QGEN. Its Form 20-F and Form 6-K disclosures cover audited annual financial statements, U.S. GAAP quarterly reports, operating and financial review, market-risk disclosures, legal proceedings, risk factors and the use of adjusted non-GAAP measures.
The filing record also includes exhibits and current reports tied to QIAGEN’s molecular diagnostics and life sciences portfolio, including sample technologies, QuantiFERON, QIAstat-Dx, QIAcuity and QIAGEN Digital Insights. Other disclosures address capital-structure actions such as a synthetic share repurchase and reverse stock split, material agreements, governance matters, exchange-listing registration notices and shareholder-facing corporate updates.
QIAGEN N.V. submitted a Form 6-K noting that it has issued a press release with details on completing a synthetic share repurchase plan. This plan combines a direct capital repayment to shareholders with a reverse stock split, which together are intended to adjust the company’s share structure while returning capital.
The press release, dated December 18, 2025, is included as Exhibit 99.1 and is incorporated by reference, meaning the detailed terms of the synthetic share repurchase and reverse stock split are provided in that accompanying document.
Wellington Management Group LLP filed an amended Schedule 13G reporting beneficial ownership in QIAGEN N.V. (QGEN) as of 09/30/2025. The filing lists 23,330,248 shares beneficially owned, representing 10.7% of the common stock.
The group reports 0 shares with sole voting or dispositive power, 19,132,735 with shared voting power, and 23,330,248 with shared dispositive power. One affiliated adviser, Wellington Management Company LLP, reports 6.9%. The securities are held for clients of Wellington-affiliated advisers, and the certification states they were acquired and are held in the ordinary course and not to change or influence control.
QIAGEN N.V. filed a Form 6-K summarizing several developments and furnishing related press releases as exhibits. The company announced a definitive agreement to fully acquire Parse Biosciences, a plan to return up to approximately $500 million to shareholders through a synthetic share repurchase, and that Thierry Bernard will step down as Chief Executive Officer and Managing Director.
QIAGEN also furnished a press release with unaudited financial results for the third quarter ended September 30, 2025. The filing reiterates the company’s use of non-GAAP and constant currency measures alongside GAAP results, noting reconciliations accompany the press release and that forward-looking non-GAAP reconciliations are not provided due to variability.
QIAGEN N.V. filed a Form 6-K as a foreign private issuer to provide its U.S. GAAP quarterly report for the three and six months ended June 30, 2025.
The quarterly report is furnished as Exhibit 99.1 and is incorporated by reference. The filing is signed on behalf of the company by Chief Financial Officer Roland Sackers.
Form 144 filed for QGEN reports a proposed sale of 25,000 common shares on the New York Stock Exchange with an aggregate market value of $1,220,000 and approximately 216,834,000 shares outstanding. The securities to be sold were acquired as restricted stock unit (RSU) awards on multiple dates in 2021 and 2022, with individual lots of 5,918; 5,247; 5,089; 4,253; and 4,493 shares. The filer states no securities were sold in the past three months and affirms they are not aware of undisclosed material adverse information about the issuer. The planned transaction is scheduled for approximately 08/15/2025.
QGEN Form 144 summary: This filing notifies a proposed sale under Rule 144 of 31,423 common shares by an insider brokered through Morgan Stanley Smith Barney on the NYSE, with an aggregate market value of $1,546,256.70 and an approximate sale date of 08/15/2025. The shares were acquired as performance shares on 02/28/2025. The filing also reports sales by the same person during the prior three months totaling 68,577 common shares for gross proceeds of $3,336,720.01 across trades on 08/13–08/14/2025. The filer certifies no undisclosed material adverse information.
Form 144 filed for QIAGEN N.V. (QGEN) reports a proposed sale of 18,577 common shares with an aggregate market value of $910,286, to be sold on 08/14/2025 on the NYSE. The filing lists total outstanding shares of 216,556,000, and shows the securities were acquired as performance shares on 02/21/2023 (9,756 shares), 02/27/2025 (4,736 shares) and 02/28/2025 (4,085 shares). The form also discloses two sales on 08/13/2025 by Roland Sackers totaling 50,000 shares for combined gross proceeds of $2,456,435.00. The filer signs the standard attestation that no material nonpublic information is known.
Qiagen N.V. (QGEN) disclosure shows a proposed sale of 50,000 common shares through Morgan Stanley Smith Barney LLC with an aggregate market value of $2,456,435.00. With 216,556,000 shares outstanding, the proposed block represents roughly 0.023% of the company. The shares were received as performance shares on 02/21/2023 (15,378 shares) and 02/28/2023 (34,622 shares). The filing reports “Nothing to Report” for sales in the past three months and includes the seller's attestation that they are not aware of undisclosed material adverse information.
Wellington Management entities disclosed beneficial ownership of 26,023,940 shares of Qiagen N.V. (CUSIP N72482206), equal to 11.95% of the outstanding common stock. The filing shows shared voting power of 20,289,753 shares and shared dispositive power of 26,023,940 shares. The reporting persons are multiple Wellington entities, some classified as holding companies and one as an investment adviser, and the securities are owned of record by clients of Wellington investment advisers. The statement affirms the holdings are held in the ordinary course of business and not for the purpose of changing or influencing issuer control.